Brongo: Dosing, Side Effect & Interaction

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Thai FDA Category Presentation/Packing Local Product Insert

Concise Prescribing Info

Contents

Carbocisteine lysine

Indications/Uses

Muco-regulator w/ mucolytic & fluidifying effect. Hyper/hypo-viscous mucus conditions. Acute & chronic disorders of upper & lower resp tract eg, COPD & prevention of acute exacerbations associated w/ chronic obstructive bronchitis. ENT disorders eg, pharyngitis, tonsilitis, laryngitis, rhinopharyngitis, otitis, sinusitis.

Click to view Brongo detailed prescribing information

Dosage/Direction for Use

Adult 30 mL (equiv to 2.7 g carbocisteine lysine salt) once daily or 15 mL bid. May increase administration to tid. Childn ≥5 yr 5 mL bid, 1-5 yr 2.5 mL bid. May increase administration to tid.

Click to view Brongo detailed prescribing information

Overdosage

View Brongo overdosage for action to be taken in the event of an overdose.

Administration

May be taken with or without food.

Contraindications

Hypersensitivity. Active peptic or duodenal ulcer.

Click to view Brongo detailed prescribing information

Special Precautions

Increased cough & sputum. Individuals susceptible to gastroduodenal ulcers. Patients w/ severe resp failure. Asthmatic patients w/ history of bronchospasm. Concomitant use w/ an antitussive is not recommended. Not recommended during 1st trimester of pregnancy. Lactation. Not recommended in neonates & infants. Debilitated patients.

Click to view Brongo detailed prescribing information

Use In Pregnancy & Lactation

Click to view Brongo detailed prescribing information

Adverse Reactions

GI bleeding; nausea, vomiting, diarrhoea, epigastric discomfort; anaphylactic reactions, fixed drug eruption; rash, bullous dermatitis (eg, SJS, erythema multiforme).

Click to view Brongo detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view Brongo detailed prescribing information

Storage

View Brongo storage conditions for details to ensure optimal shelf-life.

Description

View Brongo description for details of the chemical structure and excipients (inactive components).

Action

View Brongo mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Cough & Cold Preparations

ATC Classification

R05CB03 - carbocisteine ; Belongs to the class of mucolytics. Used in the treatment of wet cough.

Thai FDA Category

NDD

Presentation/Packing

Form

Brongo syr 450 mg/5 mL

Packing/Price

((fruity flavor)) 40 mL x 1's

Brongo

carbocisteine

Manufacturer:

Biolab